Welcome to our dedicated page for Logicbio Therapeutics SEC filings (Ticker: LOGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LogicBio Therapeutics’ SEC reports are packed with gene-editing science, FDA correspondence and licensing clauses that can overwhelm even seasoned biotech analysts. Missing a single footnote on trial enrollment or cash runway could mean overlooking a material risk. If you have ever searched for “LogicBio Therapeutics SEC filings explained simply,” you know it is hard to extract what matters from hundreds of pages.
Stock Titan solves that problem. Our AI digests every LogicBio Therapeutics quarterly earnings report 10-Q filing, LogicBio Therapeutics annual report 10-K simplified, and LogicBio Therapeutics 8-K material events explained, turning technical jargon into clear summaries that highlight clinical milestones, orphan-drug designations and collaboration revenue. Need real-time alerts? The moment a director files LogicBio Therapeutics Form 4 insider transactions real-time, you will see it alongside context on prior trades and upcoming data readouts. You can also explore the definitive proxy for LogicBio Therapeutics proxy statement executive compensation without wading through legal boilerplate.
Whether you are tracking cash burn before the next Phase 1/2 readout, comparing R&D spend quarter-over-quarter, or monitoring LogicBio Therapeutics executive stock transactions Form 4, our platform keeps every document in one place and updated within seconds of hitting EDGAR. Use keyword search, AI-powered highlights and side-by-side comparisons for “understanding LogicBio Therapeutics SEC documents with AI.” From LogicBio Therapeutics insider trading Form 4 transactions to LogicBio Therapeutics earnings report filing analysis, the insights you need are ready—no more skimming dense PDFs.
ContextLogic Holdings Inc. (LOGC) filed a Form 4 reporting an automatic sale of shares by its Chief Financial Officer. On November 19, 2025, the CFO disposed of 4,485 shares of common stock in a transaction coded "F" at a price of $7.05 per share to cover tax withholding obligations tied to restricted stock units (RSUs).
The filing also notes that on November 14, 2025, 11,870 RSUs converted into an equal number of common shares at a $0 exercise price, leaving the reporting person with 7,385 shares of common stock held directly after the transactions. Half of the RSUs vested on November 14, 2025, and the remaining 50% are scheduled to vest on May 15, 2026, with settlement to occur on or after vesting, and in any event within 60 days of each vesting date unless a later date is agreed in writing.
ContextLogic Holdings Inc. (LOGC) Chief Financial Officer reported the vesting and settlement of restricted stock units. On 11/14/2025, 11,870 RSUs converted into 11,870 shares of common stock at an exercise price of $0, and these shares are now held directly. The RSUs represent a right to receive one share of common stock for each unit upon vesting. According to the vesting schedule, 50% of the RSUs vested on November 14, 2025, and the remaining 50% are scheduled to vest on May 15, 2026, with vested RSUs settling on or following each vesting date and within 60 days of that date unless a later settlement date is agreed in writing.
ContextLogic Holdings Inc. (LOGC) reported Q3 2025 results reflecting its post‑divestiture structure. Revenue was $0 as the company no longer operates the prior marketplace and logistics business. Operating expenses were $3 million and interest and other income was $2 million, resulting in a net loss of $1 million for the quarter.
As of September 30, 2025, cash and cash equivalents were $102 million and marketable securities were $116 million, all in U.S. Treasury bills, money market funds, and cash deposits. Stockholders’ equity was $141 million, and redeemable non‑controlling interest related to Preferred Units in a subsidiary was $77 million. Shares outstanding were 26,682,233 as of September 30, 2025.
The company completed a holding‑company reorganization on August 7, 2025 and now trades on the OTCQB as “LOGC.” Transfer restrictions at 4.9% ownership thresholds aim to preserve net operating losses, which increased to $2.9 billion following the 2024 tax filing. In March 2025, a subsidiary issued Preferred Units (net proceeds $72 million) that accrue 4% before any acquisition and 8% after, and are convertible into common units under defined terms.
ContextLogic Holdings Inc. furnished a Form 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The release is included as Exhibit 99.1.
The disclosure is provided under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), and is expressly stated as furnished, not filed under the Exchange Act.
FAQ
What is the current stock price of Logicbio Therapeutics (LOGC)?
What is the market cap of Logicbio Therapeutics (LOGC)?
